Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
AUTOR(ES)
Rosenberg, Jonathan E.
FONTE
American Society of Clinical Oncology
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2698016Documentos Relacionados
- Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer
- Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
- Editorial Comment: Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223
- Castration-resistant prostate cancer: systemic therapy in 2012
- National Consensus on Non-metastatic Castration-Resistant Prostate Cancer: more than just a snapshot
